StockGlow

Cybin D/B/A Helus Pharma (HELP)

Develops psilocybin-based drugs to treat depression and anxiety disorders.

$7.60-0.01%Healthcare
Compare HELP with
StockGlow Score
93
Bullish
BearishBullish
1 year ago+0.5%

The outlook

HELP is trading at $7.60 with unanimous Strong Buy analyst consensus from nine analysts. The stock sits well above its short- and long-term moving averages and is positioned in the upper half of its 52-week range. The average analyst price target sits roughly 362% above the current price.

What’s behind the score

Analyst consensusStrong Buy — 1.0 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range72% of the way from its 52-week low to high
Price targetAvg target +362% vs current price

Analyst price target

~12-month · 9 analysts
$35.13average target+362.2% vs now
Now $7.60
Low $7.97High $69.77

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$471.1M
52-wk high
$9.12
52-wk low
$3.76
50-day avg
$5.50
200-day avg
$6.05
Trailing P/E
—

Similar stocks

CMPSCOMPASS Pathways plc$10.85-3.73%DFTXDefinium Therapeutics, Inc.$41.96-1.62%AACGATA Creativity Global$0.97+5.43%GHRSGH Research PLC$27.96+0.76%ATAIAtaiBeckley Inc.$7.18+0.14%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy